e-learning
resources
Munich 2014
Sunday, 07.09.2014
Pathology and prognostic factors of thoracic tumours
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Correlation between the simultaneus expression of HER2 and PTEN and the risk of development of metastasis in NSCLC
A. Stamatelopoulos, E. Tsiambas, N. Atzoulatos, P. Michos, I. Gakidis, D. Bouros (Athens, Alexandroupolis, Greece)
Source:
International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Session:
Pathology and prognostic factors of thoracic tumours
Session type:
Poster Discussion
Number:
509
Disease area:
Thoracic oncology
Abstract
HER2/neu overexpression due to gene amplification is an important factor in breast cancer, modifying the sensitivity to anti-HER2 monoclonal antibody therapy. The clinical significance of HER2 expression in non small cell lung carcinoma (NSCLC) is currently under evaluation. The tumor suppressor gene PTEN negatively regulates the HER2/PI3K/Akt signalling pathway. The purpose of this study was to evaluate the role of simultaneous alteration in HER2 and PTEN protein expression in relation to biological behaviour of NSCLCs.MATERIALS AND METHOD:Protein expression was determined by immunohistochemistry in 82 NSCLC cases along with CISH for HER2 gene analysis and detection of chromosome 17 aneuploidy. Patients were followed-up for a period of 34 to 41 months after surgery.RESULTS:HER2 overexpression (2+/3+ score) was detected in 23 (27.9%) patients while loss of PTEN expression was observed in 32 (39.3%) cases, low expression in 39 (47.6%) and overexpression in 11(13.1%). Simultaneous HER2 overexpression and PTEN low/loss of expression were correlated with metastasis (71.4% vs 36.2% p=0.03) . Analysis in the subgroup of 30 patients of pTNM stage III with lymph node status N1 or N2 revealed that there was a relationship between the number of positive regional lymph node groups and simultaneous deregulation of the two genes (p=0.04). Multivariate analysis determined that HER2 overexpression was associated with an increasing risk of developing metastases (OR: 4.3; 95%CI: 1.2-15.9; p: 0.03) while PTEN overexpression was associated with lower risk (OR: 0.1; 95%CI: 0.1, 1.0; p: 0.05).
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Stamatelopoulos, E. Tsiambas, N. Atzoulatos, P. Michos, I. Gakidis, D. Bouros (Athens, Alexandroupolis, Greece). Correlation between the simultaneus expression of HER2 and PTEN and the risk of development of metastasis in NSCLC. Eur Respir J 2014; 44: Suppl. 58, 509
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
Related content which might interest you:
Investigation of survivin gene expression in non small cell lung cancer
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level?
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Differences in expression and prognostic values of p16(ink) and VEGF in squamous and adenocarcinoma of the lung
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Gene expression of EGFR, MINA53,MEN1 and MTOR in NSCLCs
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
MET genetic lesions in NSCLC are functional markers of early hematogenous spreading and radioresistance
Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer
Year: 2015
The roles of Ki-67, p53, transforming growth factor- and lysyl oxidase in the metastasis of lung cancer
Source: International Congress 2014 – Improving diagnosis of thoracic tumours
Year: 2014
Prognostic value and functional characterization of miR-141 and miR-200c expression levels in resected NSCL
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
The prognostic impact of PD1 and PDL1 expression in non-small cell lung cancer
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Immunohistochemical expression of nuclear factor kappa-B/p65 and cyclooxygenase-2 in non-small cell lung cancer patients: Prognostic value and impact on survival
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
beta-F1-ATPase expression as a prognostic factor for resected non-small cell lung cancer
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Potential genetic markers for the early diagnosis of peripheral and metastatic lung cancer
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
Expression analysis of miR-21 in Bulgarian patients with non-small cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
Prognostic value of survivin gene promoter polymorphisms in non-small cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
Simultaneous EGFR and VEGF alterations in non-small cell lung carcinoma based on tissue microarrays
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Breast metastasis from primary EGFR-mutated lung carcinoma or primary tumor?
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016
Prognostic value of EGFR mutation in NSCLC in surgical stage
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Cytological samples for the study of EGFR, KRAS and ALK mutations in non-small cell lung cancer
Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Year: 2013
mRNA biomarker screening in pulmonary tumors showing neuroendocrine differentiation
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Comprehensive evaluation of nuclear factor-κΒ expression patterns in non-small cell lung cancer
Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept